2022-07-05-世界卫生组织-Weekly_epidemiological_update_on_COVID-19_-_6_July_2022_20页_1mb

COVID-19 Weekly Epidemiological Update Summary

This summary analyzes the WHO COVID-19 Weekly Epidemiological Update, Edition 99, dated 6 July 2022, which presents data as of 3 July 2022.

Global Overview

• G lobal weekly COVID-19 cases rose for a fourth consecutive week to 4.6 million, similar to the previous week's count. New deaths decreased by 12% to just over 8100.
• Trends are cautious due to evolving testing strategies lowering overall test volumes and case detection.
• Total confirmed cases exceed 546 million, and reported deaths top 6.3 million globally.

Regional Trends (As of 3 July 2022)

• The European Region saw the largest decrease in cases (-18%) and deaths (-13%). The Region of the Americas and Western Pacific also showed significant declines (-18% and -4% in cases, -13% and -12% in deaths).
• Cases increased in the Eastern Mediterranean Region (+29%) and South-East Asia Region (+20%).
• Deaths increased in the Eastern Mediterranean (+34%) and South-East Asia (+16%) regions and decreased significantly elsewhere (Africa -50%, Americas -13%, Europe -12%, Western Pacific -12%).

Country-Level Data (As of 3 July 2022)

• Top countries by new cases: France (+33%), Italy (+50%), USA (-29%), Germany (-2%), Brazil (-4%).
• Countries with the highest case proportion increase: Kosovo (+327%), Occupied Palestinian Territory (+235%), Kyrgyzstan (+314%), Tunisia (+141%).
• Top countries by new deaths: USA (-19%), Brazil (-10%), China (-30%), Italy (+21%), Russia (-14%).

Special Focus: Variants

• Omicron remains dominant (92% of sequences, >50% of sequences by week 25). BA.5 is rapidly rising globally (now at 12%).
• BA.4 is increasing but at a slower rate than BA.5.
• BA.2 and its sub-lineage BA.2.12.1 are declining but have been associated with case surges in some regions.
• No evidence indicates major differences in clinical severity compared to BA.2.
• Specific mutations lead to reduced neutralizing antibody activity (7-7.5 fold reduction vs BA.1) and neutralization resistance to treatments like cilgavimab, casirivimab-imdevimab, and sotrovimab (though higher levels against other anti-RBD monoclonals).
• SGTF was maintained, and Ag-RDT sensitivity remained high.
• Considerable diagnostic and therapeutic escape reduction exists.

Vaccines and Effectiveness

• Vaccine Effectiveness (VE) against the Omicron variant shows reduced protection overall compared to earlier variants, especially against infection/symptomatic disease, with significant decline post-vaccination over time. Severe disease VE remains relatively high.
• Primary series mRNA vaccines showed higher SE against severe disease than infection.
• First booster significantly improves protection for all outcomes, slowing VE decline (though drop still occurs) and raises VE against severe disease to levels above 70% in many cases.
• Booster Efficacy varies by vaccine type. mRNA boosters generally offer higher protection against severe disease, while effect may wane rapidly against infection/infection. Protection levels vary between original/different primary vaccines and specific brands.

WHO Regional Overviews

• Region of the Americas: Cases & deaths decreased significantly.
• African Region: Cases decreased by 50%, deaths by 100%.
• Eastern Mediterranean Region: Cases rose by 29%, deaths rose by 34%.
• European Region: Cases & deaths decreased.
• South-East Asia Region: Cases & deaths increased.
• Western Pacific Region: Cases increased slightly, deaths decreased slightly.
• Specific case/death counts by country vary significantly across regions, influenced by different testing/vaccination levels.

Annex Notes & References

• Data are based on official national reports, subject to verification and delays.
• References 1-39 detail studies on variant transmission/disease, vaccine characterization, neutralization assays (including fold-reduction classifications), and VE studies (primarily pre-print/pooled data) cited in the report.

This summary provides a concise overview of the global COVID-19 situation and key updates on variants and vaccines based on the specified WH 0 report edition.